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Abstract 
The majority of those who experience clinical anxiety and depressive symptoms do not receive treatment. 
Studies investigating inequalities in treatment outcomes rarely consider that individuals respond 
differently to their experience of the environment. Indeed, individuals actively select their experiences. 
Therefore, much of our environment is under genetic influence, via our behaviour. If genes influence who 
seeks and receives treatment, selection bias will confound genomic studies of treatment response. 
Furthermore, if some individuals are at high genetic risk of seeking but not commencing treatment, then 
greater efforts could be made to engage them.  We explored the role of genetic influences on four lifetime 
treatment-seeking behaviours (treatment-seeking, treatment-receipt, self-help, self-medication) in 
participants of the UK Biobank (sample size range: 48,106 - 75,322). We found that treatment-related 
behaviours were modestly heritable in these data. Nonetheless, we observed interesting genetic overlap 
between lifetime treatment related-phenotypes and psychiatric disorders, symptoms and behavioural 
traits.  
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Introduction 
One in six adults experience clinical anxiety and/or depressive symptoms in any given week in 
the UK, but only one in three of those in need of treatment report currently using a treatment (McManus et 
al. 2016). The disparity between the number of individuals with clinical symptoms and those that receive 
treatment is called the treatment gap (Kohn et al. 2004). A number of studies have estimated that as 
many as 75% of individuals who have a 12 month diagnosis of depression do not receive treatment 
(Chisholm et al. 2016; Thornicroft 2008; Thornicroft et al. 2017). This is despite many such individuals 
acknowledging a need for treatment and having contacted services. Some evidence for demographic 
inequalities in who receives treatment exists. Within the UK, individuals who are White British, female, or 
middle-aged were more likely to receive treatment than those who were not (McManus et al. 2016). 
Individuals from lower socioeconomic backgrounds are more likely to have sought but not actually 
received treatment (McManus et al. 2016; Delgadillo et al. 2016). There are many reasons why 
individuals might not seek treatment, such as a lack of knowledge to identify clinical symptoms (i.e. poor 
mental-health literacy), lack of awareness about treatment options, negative beliefs about the 
effectiveness of treatment, and stigma (i.e., perceived prejudice and/or discrimination against people 
diagnosed with mental health conditions; (Henderson, Evans-Lacko, and Thornicroft 2013). 
Twin studies have shown that a proportion of the variation in nearly all complex human traits can 
be explained by genetic variation (on average ~50%; Polderman et al. 2015). This is known as heritability, 
the proportion of variation in an observable trait attributed to genetic factors, in a given population at a 
particular time-point (Visscher, Hill, and Wray 2008). Analysis of genome-wide genetic data in many traits 
has shown that a proportion of heritability can be explained by the additive effects of common genetic 
variants (genetic variation in 1% of the genome, that occurs in >1% of the population). Variation in 
disorders (e.g. Anxiety and Major Depressive Disorder), personality traits, (e.g. neuroticism, openness, 
conscientiousness), and life outcomes (e.g. educational attainment) can be explained by common genetic 
variation (common genetic variant heritability; h2SNP range: 5-30%; Brainstorm Consortium et al. 2018). 
Studies investigating causes of treatment inequalities do not always account for the fact that 
individuals differ in their response to the environment (Spinath and Bleidorn 2017). Whether an individual 
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receives treatment, and the type of treatment they receive, are components of their environment. Many 
environmental influences have been found to be heritable (Kendler and Baker 2007). Environments 
known to be heritable include experience of stressful life events, social support and marital quality 
(Kendler and Baker 2007). Of particular note, the genetic influences on such environmental experiences 
(e.g. stressful life events or social deprivation) overlap considerably with those on traits of interest such as 
depression (Thapar, Harold, and McGuffin 1998; Hill et al. 2016).  This indicates that genetic variation 
influences correlations between behaviour and life experiences. In other words, genetic factors influence 
behaviour, which plays a major role in shaping our environment, so called gene-environment correlation. 
One approach to understanding how genetic influences on different traits relate to one another is 
to examine their genetic correlation. Exploring genetic correlations allows us to garner information about 
where genetic influences on the trait of interest (e.g. treatment seeking) come from. Shared genetic 
variation can indicate that specific genetic variants influence the two traits independently. Alternatively, in 
the case where trait A directly influences trait B, any genetic effects on trait A will also influence trait B 
(Gage et al. 2016). For example, genetic effects might impact on both anxiety symptoms and treatment 
seeking. Genes influencing greater symptom severity are likely to influence need for treatment. Different 
genes influencing personality traits, for example openness, might also lead an individual to be more open 
about their experiences, in turn promoting treatment-seeking. Indeed, the decision to seek and then 
commence treatment, may depend in part on genetically influenced individual characteristics, which 
themselves impact on treatment-seeking behaviours.  
Whether or not genes influence treatment-seeking should also be of particular interest to 
researchers investigating genetic influences on treatment response. It will be important to identify genetic 
influences on treatment-seeking and control for them in genomic studies of treatment response. It is also 
important to consider that only those who seek treatment will receive it, which may have implications for 
studies and trials investigating treatment efficacy. Those who do not seek treatment (or who seek but do 
not receive treatment) will be excluded from such analyses, which could bias estimated effects of 
treatment. For example, belief in the positive effects of treatment has been linked with adherence to 
treatment and favourable response (Ownby et al. 2014; J. Carter et al. 2006; J. D. Carter et al. 2015; 
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Lambert and Barley 2001). Whereas, negative beliefs about treatment have been associated with 
reluctance to seek help (Henderson, Evans-Lacko, and Thornicroft 2013). By not including individuals 
with negative beliefs about treatment efficacy, the positive effects of treatment might be overestimated. 
Furthermore, if individuals who need treatment are at high genetic risk of not taking up treatment, then 
greater efforts could be made to engage them and improve compliance with treatment. 
We explored the role of genetic influences on lifetime treatment-seeking behaviours in a large UK 
population study, the UK Biobank. We defined four treatment-related phenotypes in response to 
symptoms of anxiety or depression; treatment-seeking (have you ever from sought help from a 
professional?), treatment-receipt (have you ever received talking therapy or prescription medication?), 
self-help (have you ever used a structured therapeutic activity or over the counter medications to 
alleviate symptoms?), and self-medication (have you ever used drugs or alcohol to alleviate 
symptoms?). We estimated the common variant heritability of these phenotypes and examined genetic 
correlations with psychiatric disorders and behavioural traits. We aimed to determine whether treatment-
related phenotypes have genetic influences distinct from those influencing symptoms. Therefore, where 
possible we stratified our analyses based on whether individuals meet diagnostic criteria for an anxiety or 
depressive disorder diagnosis. Here, we specifically examined whether there were genetic influences on 
reluctance to seek treatment in those who need it (‘cases’) and on seeking treatment despite not meeting 
diagnostic criteria (‘controls’). 
 
Methods 
Sample & Phenotypes 
 The UK Biobank is a UK population study of approximately half a million individuals aged 
between 40 and 70 (Allen et al. 2014). The study originally assessed a range of health-related 
phenotypes and biological measures including genome-wide genotype. More recently a follow-up, online 
mental health questionnaire was completed by 157,366 participants (Davis et al. 2018). The mental 
health questionnaire assesses common mental health conditions, including lifetime symptoms of anxiety 
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and depression, and experiences of healthcare. Specifically, participants who reported having worried for 
a period of six months or longer, having worried more than most people would in a similar situation, 
having prolonged loss of interest in normal activities, or prolonged feelings of sadness or depression they 
were asked: "Did you ever tell a professional about these problems (medical doctor, psychologist, social 
worker, counsellor, nurse, clergy, or other helping professional)?".  
From these data, we defined four treatment related phenotypes (see supplemental material for 
sample selection and phenotype definition workflow). Treatment-seeking participants reported on 
seeking help from a professional. Treatment-receipt was defined from participants who reported on 
seeking help and then receiving either prescribed medication or talking therapy for their symptoms. Self-
help participants reported engaging in a structured therapeutic activity (e.g. mindfulness or yoga) or using 
over-the-counter medications to help with their symptoms. Self-medication was defined from those who 
reported using alcohol or illicit drugs in response to their symptoms.  
For stratified analyses, cases were defined as those who reported sufficient severity and impact 
of symptoms to meet lifetime criteria for likely DSM-IV for either generalised anxiety disorder or major 
depressive disorder diagnoses. The self-report items were based on questions derived from the 
Composite International Diagnostic Interview (CIDI; i.e., probable lifetime diagnosis; as described in 
(Purves et al. 2017; Coleman et al. 2018). Cases were excluded if they self-report lifetime diagnoses of 
schizophrenia, other psychoses or bipolar disorder. Controls were defined as those not meeting criteria 
for either anxiety, or depression diagnoses, and were excluded if they reported a diagnosis of any 
psychiatric disorder. Individuals were excluded from analyses if they did not complete mental health 
online questionnaire (n=157,366), or if they did not endorse at least one of the four core common mental 
health screening items (worried for a period of more than six-months, worry more than most people in a 
particular situation, loss of interest in usual activities, prolonged feelings of sadness; Max n=75,322). It 
should be noted that our 'controls' endorse at least one of the four core common mental health screening 
items (worried for a period of more than six-months, worry more than most people in a particular situation, 
loss of interest in usual activities, prolonged feelings of sadness), and as such are not symptom-free. This 
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is a necessary condition for respondents to report on treatment-seeking in the mental health 
questionnaire. 
The whole UK Biobank sample (N=502,616) were also asked the question: “Have you ever seen 
a GP / psychiatrist for nerves, anxiety, tension or depression?”. From this data, we defined a formal 
treatment-seeking phenotype, i.e. participants who reported on seeking help specifically from their doctor 
or a psychiatrist. Data were available for 391,213 participants reporting on formal treatment seeking. For 
these participants, information on symptoms and diagnoses was not available. However, we saw this as 
an opportunity to test the reproducibility of our primary treatment-seeking analyses in a much larger 
sample. Results from these analyses are presented in the supplementary material. 
Genetic data 
 Genetic data were drawn from the full release of the UK Biobank data (n=487,410; Bycroft et al. 
2017). Standard quality control described previously (Coleman et al. 2018) and presented in full in the 
supplement were applied to the full data. Analyses were limited to common genetic variants imputed to 
the Haplotype Reference Consortium reference panel with high confidence (McCarthy et al. 2016). 
Participants were excluded if they had unusual levels of missingness or heterozygosity, they were related 
to another individual in the dataset, or their phenotypic and genotypic gender information was discordant. 
All analyses were limited to individuals of White Western European ancestry. This is because 95% of 
respondents to the mental health questionnaire are of White Western European ancestry. Therefore, we 
did not have sample sizes required to perform informative genomic analyses in other ancestry groups. 
Analyses 
 All genomic analyses were performed on the residuals from the regression of the binary treatment 
related phenotypes and age, sex, six population principal components, batch and assessment centre. 
Analyses were performed in the whole sample and then stratified by lifetime diagnosis, and also by sex. 
We performed genome-wide association analyses to estimate the effects of 9.94 million genome-wide 
genetic variants on each phenotype (BGENIE v1.2; Bycroft et al. 2017). We then estimated how much 
phenotypic variance could be explained by common genome-wide genetic variants, using linkage 
disequilibrium score regression (LDSC; Bulik-Sullivan et al. 2015), converting to the liability scale at the 
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full range of population prevalence estimates (Bulik-Sullivan et al. 2015). We tested differences between 
heritabilities using a block-jackknife approach (supplementary methods).  
We also estimated genetic correlations (rg) between treatment related phenotypes and also with a 
range of psychiatric disorders, personality and behavioural traits. We selected a range of well-powered 
GWAS of psychiatric, behavioural and related traits to provide a thorough examination of the genetic 
overlap between treatment related phenotypes and behaviour, psychopathology (for the full list, including 
references see supplement and/or Figure 2). Significance was assessed after Bonferroni multiple testing 
correction. 
 
Results 
Phenotype distribution 
 Phenotype and genotype data were available for participants reporting on treatment-seeking 
(n=71,416), treatment-receipt (n=48,106), self-help (n=75,322), and self-medication (n=75,128; Table 1). 
Based on the self-report items, the lifetime prevalence of generalised anxiety disorder and major 
depressive disorder was 11% and 38% respectively (in individuals seeking treatment). Combined, the 
prevalence of experiencing a common mental disorder across the lifespan was 41%. All participants in 
our primary sample reported experiencing at least one core symptom of anxiety or depression across 
their lifetime. The majority (67%) of the sample reported informing a professional about their symptoms 
and most of these individuals (84%) reported receiving treatment for their symptoms (i.e. 56% of the total 
sample). Of the whole sample, 14% report utilising some form of self-help approach such as exercise, 
mindfulness or over-the-counter medication, and 14% report self-medicating with alcohol or drugs.  
 
 
Table 1. Treatment seeking phenotype distributions in the full sample and stratified by CIDI derived 
lifetime diagnosis of a common mental disorder status and sex 
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   Lifetime diagnosis Sex 
  N (a) Controls (b) Cases (b) Female (b) Male (b) 
Treatment-seeking 
No 23,362 16,789 4,222 12,528 10,834 
Yes 48,054 14,700 25,810 32,706 15,348 
Prev. (*) 0.67 0.47 0.86 0.72 0.59 
Treatment-receipt 
No 7,670 4,005 2,552 4,914 2,756 
Yes 40,436 10,715 23,283 27,829 12,607 
Prev. (*) 0.84 0.73 0.9 0.85 0.82 
Self-help 
No 60,091 29,451 22,515 36,132 23,959 
Yes 15,231 4,317 8,519 11,587 3,644 
Prev. (*) 0.2 0.13 0.27 0.24 0.13 
Self-medication 
No 64,171 30,642 24,714 41,670 22,501 
Yes 10,957 3,042 6,252 5,924 5,033 
Prev. (*) 0.15 0.09 0.2 0.12 0.18 
(*) Proportion of individuals that endorse each phenotype in (a) individuals who report on the 
phenotype, drawn from the full sample and (b) individuals who report on the phenotype, drawn from 
each strata; No = never in their lifetime; Yes = at least once in their lifetime 
 
Table 2. Overlap between treatment seeking phenotypes 
  Treatment-seeking (i)       
  No Yes %(a)       
Treatment-
receipt (ii) 
No 0 7,665 100       
Yes 0 40,389 100 Treatment-receipt (i)    
%(b) - 84  No Yes %(a)    
Self-help (ii) 
No 20,831 35,971 63.3 6,100 29,916 83.1    
Yes 2,521 12,056 82.7 1,557 10,506 87.1 Self-help (i) 
%(b) 10.8 25.1  20.3 26  No Yes %(a) 
Self-
medication (ii) 
No 20,517 40,324 66.3 6,684 33,685 83.4 52,453 11,708 18.2 
Yes 2,772 7,603 73.3 933 6,677 87.7 7,467 3,488 31.8 
%(b) 11.9 15.9  12.2 16.5  12.5 23  
(a) % of individuals who endorse phenotype (i) out of the total number of individuals who either have never 
endorsed (0) or have endorsed (1) phenotype (ii); (b) % of individuals who endorse phenotype (ii) out of the 
total number of individuals who either (0) have never endorsed or (1) have endorsed phenotype (i); No = 
never in their lifetime; Yes = at least once in their lifetime 
 
Heritability analyses 
 Our analyses indicate that treatment-seeking is modestly heritable. In the whole cohort we detect 
small, but significant estimates of common variant heritability for treatment-seeking (h2SNP =3.9% se=.7%), 
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self-medication (h2SNP =3.4% se=.7%) and self-help (h2SNP =2% se=.6%; Figure 1a). The heritability of 
receiving treatment (as opposed to seeking treatment but not receiving it) was smaller than our analysis 
was powered to detect (80% power to detect h2SNP=4.5%; 70% power to detect h2SNP =4%; GCTA power 
calculator: Hemani and Yang 2017).  
We also estimated the heritability of all the treatment-related phenotypes in cases and controls, 
and in males and females separately (Figure 1a). However, in these smaller sub samples, the estimates 
are small and standard errors are large and overlap substantially. This could suggest that the estimates 
are not significantly different between strata (cases/controls; males/females). It is more likely that we are 
underpowered to detect subtle differences. 
 The lifetime prevalences of treatment-related phenotypes are difficult to estimate, so we 
converted estimates to the liability scale across the full range of population prevalence (Figure 1b).  
Heritability on the liability scale ranges from 2% to 9% for treatment-seeking, 2% to 5% for self-medication 
and 1% to 6% for self-help. Again, the standard errors of the heritability estimates overlap substantially 
when the analyses are stratified by case-control status.  
Genetic correlations 
 Treatment-seeking, self-help and self-medication all show modest genetic correlations with one 
another, that are not significant after multiple testing correction. Treatment-seeking has genetic 
correlations with both self-medication (rg=.36, se=.13) and self-help (rg=.52, se=.15). Self-medication has 
a genetic correlation with self-help (rg=.65, se=.17). Treatment-seeking has significant, positive genetic 
correlations with anxiety disorders (Purves et al. 2017), major depression (Wray et al. 2018) and related 
traits (Figure 2). Self-help has positive genetic correlations with educational attainment (Lee et al. 2018), 
schizophrenia (Ripke et al. 2014), bipolar disorder (Psychiatric GWAS Consortium Bipolar Disorder 
Working Group 2011), cross disorder psychopathology (Cross-Disorder Group of the Psychiatric 
Genomics Consortium 2013), anxiety disorders (rg~.5; Figure 2) and a negative genetic correlation with 
body mass index (rg=-.24; (Yengo et al. 2018). Self-medication has significant positive genetic 
correlations with social deprivation (Hill et al. 2016), cannabis use (Stringer et al. 2016), schizophrenia, 
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alcohol use (Schumann et al. 2016) and alcohol dependence (Walters et al. 2018) (range rg=.26-.62; 
Figure 2). 
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Figure 1 (a) Observed common genetic variant heritability estimates of treatment-seeking phenotypes in 
the whole cohort, and stratified by case/control status and sex; (b) Common genetic variant heritability 
curves: heritability estimates of treatment-seeking phenotypes converted to the liability scale at the full 
range of population prevalence 
(a) 
 
 
(b) 
  
Note: error bars represent standard errors. Overlapping standard errors indicate that estimates are not significantly 
different between strata (tested formally via block jackknife; see supplement). Negative estimates indicate that the 
heritability is smaller than our analyses were powered to detect. Heritability estimates, intercept estimates and 
standard errors are presented in the supplement. Heritability on the liability scale peaks at 50% population 
prevalence. A deviation from 50% population prevalence provides the same heritability same estimate regardless of 
direction (+/-), i.e liability scale h2 at a pop. prev of 20% is equal to liability scale h2 at a pop. prev of 80%. Thus,  
liability scale h2 is only plotted at 0-50% population prevalence.  
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Figure 2. Genetic correlations between the treatment seeking phenotypes and psychiatric, and 
behavioural traits  
 
 
 
(Note: * Bonferroni p<0.0001; error bars represent standard errors; GWAS summary statistics obtained from: major 
depressive disorder (Wray et al. 2018), anxiety disorders (Purves et al. 2017), bipolar disorder (Psychiatric GWAS 
Consortium Bipolar Disorder Working Group 2011), schizophrenia (Ripke et al. 2014), autism spectrum disorder 
(Autism Spectrum Disorders Working Group of The Psychiatric Genomics Consortium 2017), ADHD (Demontis et al. 
2018), anorexia nervosa (Bulik et al. 2017), borderline personality disorder (Witt et al. 2017), cross-disorder 
psychopathology (Cross-Disorder Group of the Psychiatric Genomics Consortium 2013), alcohol dependence 
(Walters et al. 2018), depressive symptoms ((Okbay et al. 2016), insomnia (Hammerschlag et al. 2017), tiredness 
(Deary et al. 2018), migraine (Gormley et al. 2016), BMI (Yengo et al. 2018), neuroticism and subjective well-being 
(Okbay et al. 2016), extraversion, openness to experience, and conscientiousness (de Moor et al. 2010), intelligence 
(adult IQ: (Savage et al. 2018; Benyamin et al. 2014)child IQ:(Savage et al. 2018; Benyamin et al. 2014), educational 
attainment (Lee et al. 2018), social deprivation (Hill et al. 2016), alcohol use (Schumann et al. 2016), cannabis use 
((Schumann et al. 2016; Stringer et al. 2016)) 
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We were particularly interested in understanding whether the genetic contributions to treatment-
seeking differed between anxiety/depression cases and controls. Stratified analyses resulted in reduced 
statistical power to detect genetic correlations after multiple testing correction. Estimates were not 
significantly different between the strata and standard errors overlap substantially (see Supplementary 
Figure 5). Of note, no significant genetic correlations were observed with treatment-seeking in cases, 
whereas in controls, significant positive genetic correlations were observed between treatment seeking 
and anxiety disorders, and neuroticism. This might suggest that within controls, those with higher genetic 
propensity for anxiety/neuroticism were more likely to seek treatment. In contrast, for self-help significant 
positive genetic correlations with schizophrenia and educational attainment were observed in cases: 
cases who self-help have higher genetic propensity for educational attainment and schizophrenia 
compared to cases who do not self-help (see Supplementary Figure 5).  
As a final step, we performed secondary analyses using data available from the entire UK 
Biobank sample, which assessed formal treatment-seeking. This terminology refers to when someone 
has specifically sought treatment (in this case for nerves, anxiety, tension or depression) from a medical 
professional, i.e. a GP or psychiatrist. Further details including results are presented in the supplemental 
material.  
Discussion 
 To our knowledge, this is the first study to use genomic data to examine genetic influences on 
treatment-seeking and related phenotypes. A recent study estimated that as many as 75% of individuals 
suffering with symptoms of anxiety and depression, are not receiving treatment when in need, i.e. the 
treatment gap (Thornicroft et al. 2017). We utilised participant responses to the UK Biobank mental health 
questionnaire (MHQ), which assessed adults for lifetime mental health, and their responses to mental 
health symptoms. Responses included seeking-treatment, receiving treatment, self-sourcing a remedy or 
therapeutic activity, or self-medicating with alcohol and/or drugs.  
Of the UK Biobank participants who completed the MHQ and who endorse at least one symptom 
of anxiety/depression (necessary for inclusion), the lifetime prevalence of anxiety and/or depression was 
41%. More than 85% of those who met lifetime criteria for a diagnosis, sought help, and 90% of those 
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who sought help, received treatment. Of note, 47% of individuals who have experienced an 
anxiety/depression symptom seek help, even though they do not necessarily meet criteria for a clinical 
diagnosis. Furthermore, 73% of these individuals go on to receive treatment. 
The treatment gap estimated in this sample is thus much lower than previous point prevalence 
estimates. Previous estimates from the UK suggest that at any one point in time, only ~30% of individuals 
are receiving the treatment they need (McManus et al. 2016; Thornicroft et al. 2017). There are several 
reasons why rates of treatment are much higher in this UK biobank sample than in previous studies. 
Firstly, our estimate reflects lifetime prevalence of treatment-seeking and treatment-receipt rather than the 
point prevalence estimates provided elsewhere (McManus et al. 2016; Thornicroft et al. 2017). Of course, 
individuals are more likely to have received treatment at some point in their lives than in the context of 
any single episode. As such, these estimates (90% lifetime prevalence of treatment-receipt; ~30% point 
prevalence of treatment-receipt) are not directly comparable. 
The high rates of treatment-seeking and receipt in this UK Biobank study may also be related to 
other aspects of the study design. All participants in these analyses endorsed at least one of the four core 
common mental health symptom screening items, and as such are not symptom-free. Moreover, the UK 
Biobank sample (particularly the MHQ respondent sub-sample) has more individuals from high 
socioeconomic backgrounds, and with high educational attainment, than the general UK population 
(Davis et al. 2018). These characteristics are associated with greater access to treatment (Delgadillo et 
al. 2016).   
Our goal was to determine whether lifetime treatment-seeking behaviour was influenced by 
common genetic variation, and if so, whether treatment-seeking shared genetic influences with 
psychiatric disorders and behavioural traits. Our analyses indicate that treatment-seeking, self-medication 
and self-help in response to symptoms of anxiety or depression are only modestly heritable phenotypes in 
these data. The phenotypes examined here are drawn from self-report data of lifetime experiences, thus 
we are unable to draw strong conclusions regarding genetic influence on treatment-seeking at a given 
point in time (i.e. specifically at the time of need). Future research on this topic would ideally identify 
groups of individuals with current symptoms including both those receiving and not receiving treatment. 
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This would enable a more precise estimation of the role of genetic factors with respect to accessing and 
receiving treatment. 
We used linkage disequilibrium score regression to estimate heritability and genetic correlation 
because it is less computationally demanding than other methods and enables the calculation of genetic 
correlations with external traits (such as the psychiatric disorders and behavioural traits included herein). 
However, it is likely that LD score regression underestimates heritability, relative to other contemporary 
approaches (Evans et al. 2017; Ni et al. 2018). It is also important to note that SNP heritability estimates 
only consider common genetic variation, rather than the whole genome. Twin heritability estimates, which 
capture the proportion of variation in a trait due to all genetic influences are usually at least twice that of 
SNP heritability estimates (Polderman et al. 2015; Brainstorm Consortium et al. 2018).  As such, our 
estimates are likely to represent the lower bounds of heritability for treatment-seeking and related traits.  
 The genetic overlap between treatment seeking and both anxiety and depression, as well as the 
high genetic correlations with the remaining traits, reflect a similar pattern of genetic correlations to that 
observed in genetic studies of depression and anxiety disorders themselves (Brainstorm Consortium et 
al. 2018). This suggests that the genetic influences on treatment-seeking for anxiety and depression are 
largely the same as those influencing the experience of these disorders. Indeed, one might expect that 
the primary genetic influences on treatment seeking are related to symptom severity. However, some 
individuals who need treatment do not seek it. Therefore, we were also interested in whether additional 
genetically influenced characteristics influence treatment-seeking. In order to try and examine treatment-
seeking as a behaviour independent of symptom experience, we stratified our analyses by case/control 
status. As such, we contrasted individuals who need treatment but don’t seek it, with individuals who seek 
treatment but don’t meet criteria for a diagnosis. We found no significant differences between these two 
strata. Of note, by halving our sample, we lost power to detect any subtle differences.  
We also examined genetic influences on self-help and self-medication. Self-help shows a 
similarly wide set of genetic correlations, though fewer reach statistical significance. With regard to 
psychiatric phenotypes, self-help is genetically correlated with anxiety disorder, bipolar disorder, 
schizophrenia and general psychopathology. There is also a small negative, but significant, genetic 
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correlation with BMI, suggesting that those with a genetic predisposition towards a lower weight are more 
likely to engage in self-help behaviours. This might be explained by the inclusion in the self-help category 
of exercise as a way to deal with symptoms. Interestingly self-help is positively genetically correlated with 
educational outcomes (compared to negative genetic correlations between treatment seeking and 
education). This genetic correlation remains significant in individuals with a diagnosis, but not in 
individuals without. This could suggest that genetic influences on educational achievement promote 
positive lifestyle habits (such as yoga or mindfulness) reducing symptoms and the need for clinical 
treatment. However, we cannot draw any strong conclusions from this data. Although the estimate is 
significant in individuals with a diagnosis, but not in individuals without, standard errors overlap 
substantially (Supplementary Figure 5). 
Self-medication is significantly genetically correlated with schizophrenia, alcohol dependence, 
alcohol use and cannabis use. The strong weighting towards genetic correlations with substance use 
variables is to be expected, due to the phenotypic similarity. Of particular interest, self-medication has a 
significant genetic correlation with social deprivation (rg=.55; se=.11). Genes influencing self-medication 
with drugs or alcohol thus also tend to be associated with social deprivation.  
When we performed secondary analyses examining formal treatment-seeking (i.e. specifically 
seeking treatment from a GP or psychiatrist, see supplemental material) we also detected a significant 
genetic correlation between formal treatment-seeking and social deprivation (rg=0.44, se=0.06; note: this 
genetic correlation was observed in our primary analysis, but was not significant after corrections; 
rg=0.35, se=0.1). This could reflect a greater genetic vulnerability for symptoms, need for treatment and 
self-medication among socially deprived individuals. A recent study has shown that there is greater 
demand for, but poorer access to treatment in socially deprived areas, known as the ‘inverse care law’ 
(Saxon et al. 2007; Delgadillo et al. 2016). Public health interventions aiming to reduce rates of anxiety, 
depression and incidentally alcohol and drug abuse, should focus on improving the number of individuals 
who receive and remain in treatment for anxiety and/or depression in socially deprived areas. Further 
phenotypic analyses are required to disentangle social factors associated with treatment-seeking, 
treatment-receipt and self-medication. 
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In conclusion, treatment seeking behaviours are modestly heritable. Nonetheless, we were able 
to detect interesting genetic correlations with statistical significance, which provide some preliminary 
insights on the genetic architecture of these treatment related behaviours. It should be noted that when 
the heritability of a trait is modest, estimates of genetic correlation can be inflated. As such, these 
estimates should be interpreted with caution. Further work is required to unpick the specific genetic 
influences on treatment seeking and related phenotypes. This could be facilitated by novel genomic 
methods, which allow for the combined analyses of multiple traits. Given that treatment-seeking is 
heritable, it will be necessary for genomic studies of treatment response (i.e pharmacogenetics and 
therapygenetics) to account and adjust for genetic influences on treatment-seeking in order to delineate 
the genetic mechanisms of response. In other words, when identifying genes that influence outcomes 
following treatment, it will be important to take into account genetic influences on treatment seeking so 
that these are not incorrectly thought to influence outcome. More work is needed to work out how best to 
make such an adjustment.  
Finally, our findings suggest that there is shared genetic risk for social deprivation with both 
treatment-seeking, and self-medication with drugs/alcohol. While genetics can be used to highlight 
behaviours and environments that share genetic risk, work investigating social, demographic or clinical 
barriers to treatment will be required to identify actionable predictors. Currently, whilst half of those 
treated recover, only ~30% of those with clinical symptoms receive treatment. As such, identifying 
barriers to treatment should be a public health research priority. Improving timely access to treatment will 
be essential to reduce the burden of untreated anxiety and depression. Future work would benefit from 
prospective and longitudinal study designs, collecting detailed clinical, social, demographic and genetic 
data. Such data could enable precision medicine initiatives to predict need-for-treatment and guide 
assertive outreach interventions towards those that are unlikely to seek and/or receive treatment. 
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